3 results
Approved WMOPending
Primary ObjectiveThe primary efficacy objective of the study is to assess the effect of garetosmab (10 mg/kg) versus placebo on the formation of new HO lesions from baseline to week 56, as determined by low dose CT.The primary safety objective of…
Approved WMORecruiting
Principal objectives: •To determine the safety, tolerability and recommended dose of FP- 1305 in subjects withadvanced solid tumours of the selected tumourtypes without standard treatment options.• To determine the safety, tolerability and early…
Approved WMORecruiting
To test whether immediate complete revascularization is non-inferior to staged (but within six weeks after index procedure) complete revascularization in ACS patients with multivessel disease